 | Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. They're each showing a nice estimated 1yr ROI, increasing earnings, and pay at least a minimal dividend. I believe each of these has a greater potential return than analysts currently expect. As with all of my investments, I'll start with a small positions and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market. |
Advanced Energy Industries designs, manufactures, sells, and supports power conversion and control products that transform power into various usable forms. It offers process power systems, including direct current (DC), pulsed DC, low frequency, high voltage, and radio frequency (RF) power supplies, as well as matching networks and remote plasma sources for reactive gas applications and RF instrumentation. The company also provides power control modules and thermal instrumentation products for rapid thermal processing, chemical vapor deposition, crystal growing, and other semiconductor and solar applications, as well as in chemical processing, glass manufacturing, and other general industrial power applications; and high voltage products for various applications, including semiconductor wafer processing and metrology, scientific instrumentation, mass spectrometry, industrial printing, and analytical x-ray systems. In addition, it offers repair, conversions, upgrades, and refurbishments services. The company markets and sells its products through direct sales force, independent sales representatives, and distributors in the United States, Europe, and Asia. Advanced Energy Industries, Inc. was founded in 1981 and is headquartered in Fort Collins, Colorado.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 13 August 2017 Price $71.17 1yr Target $78.20 Analysts 5 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 9.87% Yield 0.00% 1yr Tot Return 9.87% P/E 18.94 PEG 0.40 Beta 1.35 | EPS (ttm) $3.76 EPS next yr $4.60 Forward P/E 15.49 EPS next 5yr 47.40% 1yr Price Support $218.04 Market Cap $2.81 Bil Revenues $577.10 Mil Earnings $150.80 Mil Profit Margin 26.13% Quick Ratio 4.40 Current Ratio 5.10 Debt/Equity 0.00 | 1yr RevGR 16.60% 3yr RevGR 6.96% 5yr RevGR -1.32% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR 30.81% 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 26.40% ROE 38.00% |
 |
Vertex Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
(Summary) (Company) (Chart)
| 1 August 2017 Price $153.20 1yr Target $178.22 Analysts 23 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 16.33% Yield 0.00% 1yr Tot Return 16.33% P/E 146.74 PEG 2.11 Beta 1.80 | EPS (ttm) $1.04 EPS next yr $3.06 Forward P/E 50.08 EPS next 5yr 69.69% 1yr Price Support $213.25 Market Cap $38.66 Bil Revenues $2.13 Bil Earnings $259.90 Mil Profit Margin 12.15% Quick Ratio 2.60 Current Ratio 2.70 Debt/Equity 0.00 | 1yr RevGR 64.92% 3yr RevGR 11.88% 5yr RevGR 3.83% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 8.90% ROE 18.70% |
 |
RSS Feed
